DDInter150 DDInter500
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.
Azathioprine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Mercaptopurine
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Denosumab
Azathioprine {u} (Compound) upregulates {v} (Gene) ADAT1
ADAT1 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Azathioprine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Tioguanine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound) and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Mercaptopurine (Compound) and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Denosumab
Azathioprine (Compound) upregulates ADAT1 (Gene) and ADAT1 (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Denosumab